Table 2.
Association of disease activity with HRV parameters at baseline by univariate linear regression
| Independent variables | ||||
|---|---|---|---|---|
| Dependent variables | RMSSD | pNN50 | HF | LF/HF |
| BILAG |
p = 0.259 β = −0.024 |
p
= 0.019
β = −0.385 |
p
= 0.020
β = −0.108 |
p
= 0.024
β = 0.630 |
| BILAG mucocutaneous |
p = 0.870 β = 0.002 |
p = 0.124 β = −0.142 |
p = 0.313 β = −0.027 |
p = 0.695 β = 0.062 |
| BILAG musculoskeletal |
p = 0.346 β = −0.011 |
p
= 0.043
β = −0.185 |
p
= 0.010
β = −0.066 |
p = 0.100 β = 0.257 |
| SLEDAI |
p = 0.683 β = 0.005 |
p = 0.312 β = −0.101 |
p = 0.488 β = −0.020 |
p = 0.073 β = 0.301 |
| SLEDAI rash |
p = 0.977 β < 0.001 |
p = 0.420 β = −0.009 |
p = 0.170 β = −0.004 |
p = 0.206 β = 0.024 |
| SLEDAI arthritis |
p = 0.531 β < 0.001 |
p = 0.309 β = −0.010 |
p = 0.088 β = −0.005 |
p = 0.446 β = 0.013 |
| PGA |
p = 0.651 β < −0.001 |
p
= 0.014
β = −0.026 |
p = 0.154 β = −0.004 |
p = 0.062 β = 0.034 |
| SFI |
p = 0.456 β = −0.001 |
p = 0.329 β = −0.012 |
p
= 0.047
β = −0.007 |
p
= 0.008
β = 0.054 |
Abbreviations: BILAG British Isles Lupus Assessment Group, HF high-frequency power, LF/HF ratio low frequency to high frequency ratio, PGA physician global assessment, pNN50 percentage of pairs of adjacent NN intervals differing by more than 50 milliseconds, RMSSD square root of the mean of the squares of differences between adjacent NN intervals, SFI Safety of Estrogens in Lupus Erythematosus National Assessment-SLEDAI flare index, SLEDAI Systemic Lupus Erythematosus Disease Activity Index
p values <0.05 are in bold type